Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499

M. R. Smith; F. Hong; H. Li; L. I. Gordon; R. D. Gascoyne; E. M. Paietta; R. H. Advani; A. Forero-Torres; S. J. Horning; B. S. Kahl

doi:10.1038/leu.2016.305

Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by ⁹⁰Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499

M. R. Smith
, F. Hong
, H. Li
, L. I. Gordon
, R. D. Gascoyne
, E. M. Paietta
, R. H. Advani
, A. Forero-Torres
, S. J. Horning
, B. S. Kahl

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	517-519
Number of pages	3
Journal	Leukemia
Volume	31
Issue number	2
DOIs	https://doi.org/10.1038/leu.2016.305
State	Published - Feb 1 2017

Access to Document

10.1038/leu.2016.305

Cite this

Smith, M. R., Hong, F., Li, H., Gordon, L. I., Gascoyne, R. D., Paietta, E. M., Advani, R. H., Forero-Torres, A., Horning, S. J., & Kahl, B. S. (2017). Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by ⁹⁰Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia, 31(2), 517-519. https://doi.org/10.1038/leu.2016.305

@article{1fe94fa28dde4a9687df5d23addff49f,

title = "Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499",

author = "Smith, \{M. R.\} and F. Hong and H. Li and Gordon, \{L. I.\} and Gascoyne, \{R. D.\} and Paietta, \{E. M.\} and Advani, \{R. H.\} and A. Forero-Torres and Horning, \{S. J.\} and Kahl, \{B. S.\}",

note = "Funding Information: This study was coordinated by the ECOG-ACRIN Cancer Research Group (Robert L Comis, MD and Mitchell D Schnall, MD, PhD, Group Co-Chairs) and supported in part by Public Health Service Grants CA180794, CA180820, CA180853, CA189859, CA180816, CA180855, CA180799, and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. 90Y-ibritumomab tiuxetan was supplied by Spectrum Pharmaceuticals.",

year = "2017",

month = feb,

day = "1",

doi = "10.1038/leu.2016.305",

language = "English",

volume = "31",

pages = "517--519",

journal = "Leukemia",

issn = "0887-6924",

number = "2",

}

TY - JOUR

T1 - Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan

T2 - 10-year follow-up of the phase 2 ECOG-ACRIN study E1499

AU - Smith, M. R.

AU - Hong, F.

AU - Li, H.

AU - Gordon, L. I.

AU - Gascoyne, R. D.

AU - Paietta, E. M.

AU - Advani, R. H.

AU - Forero-Torres, A.

AU - Horning, S. J.

AU - Kahl, B. S.

N1 - Funding Information: This study was coordinated by the ECOG-ACRIN Cancer Research Group (Robert L Comis, MD and Mitchell D Schnall, MD, PhD, Group Co-Chairs) and supported in part by Public Health Service Grants CA180794, CA180820, CA180853, CA189859, CA180816, CA180855, CA180799, and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. 90Y-ibritumomab tiuxetan was supplied by Spectrum Pharmaceuticals.

PY - 2017/2/1

Y1 - 2017/2/1

UR - https://www.scopus.com/pages/publications/84994691879

U2 - 10.1038/leu.2016.305

DO - 10.1038/leu.2016.305

M3 - Letter

C2 - 27780968

AN - SCOPUS:84994691879

SN - 0887-6924

VL - 31

SP - 517

EP - 519

JO - Leukemia

JF - Leukemia

IS - 2

ER -

Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499

Access to Document

Other files and links

Cite this

Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by ⁹⁰Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499